Synthesis and screening of novel 4-N-heterocyclic-2-aryl-6,7,8-trimethoxyquinazolines as antiproliferative and tubulin polymerization inhibitors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synthesis and screening of novel 4-N-heterocyclic-2-aryl-6,7,8-trimethoxyquinazolines as antiproliferative and tubulin polymerization inhibitors
Authors
Keywords
-
Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 72, Issue -, Pages 116976
Publisher
Elsevier BV
Online
2022-08-28
DOI
10.1016/j.bmc.2022.116976
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disclosing the antitumour potential of the marine bromoditerpene sphaerococcenol A on distinct cancer cellular models
- (2022) Celso Alves et al. BIOMEDICINE & PHARMACOTHERAPY
- Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle
- (2021) Li-wen Ren et al. ACTA PHARMACOLOGICA SINICA
- The tubulin code and its role in controlling microtubule properties and functions
- (2020) Carsten Janke et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors
- (2020) Wen Shuai et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains
- (2019) Fatima Naaz et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Towards modern anticancer agents that interact with tubulin
- (2019) Giuseppe La Regina et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Colchicine binding site agent DJ95 overcomes drug resistance and exhibits antitumor efficacy
- (2019) Kinsie E Arnst et al. MOLECULAR PHARMACOLOGY
- Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer
- (2019) Ashish Ranjan Dwivedi et al. CURRENT DRUG TARGETS
- Synthesis of Combretastatin‐A4 Carboxamidest that Mimic Sulfonyl Piperazines by a Molecular Hybridization Approach: in vitro Cytotoxicity Evaluation and Inhibition of Tubulin Polymerization
- (2019) Chetna Jadala et al. ChemMedChem
- Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies
- (2018) Bhupinder Kumar et al. BIOORGANIC CHEMISTRY
- Synthesis and Biological Evaluation of Selenium-Containing 4-Anilinoquinazoline Derivatives as Novel Antimitotic Agents
- (2018) Baijiao An et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1
- (2018) John M. Humphrey et al. JOURNAL OF MEDICINAL CHEMISTRY
- In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents
- (2017) Mu-Tian Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth
- (2016) María-Jesús Pérez-Pérez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: Design, synthesis, biological evaluation and molecular modeling studies
- (2015) Sahil Sharma et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Synthesis and Structure–Activity Relationship Study of 1-Phenyl-1-(quinazolin-4-yl)ethanols as Anticancer Agents
- (2015) Kenta Kuroiwa et al. ACS Medicinal Chemistry Letters
- Chalcone based azacarboline analogues as novel antitubulin agents: Design, synthesis, biological evaluation and molecular modelling studies
- (2014) Sahil Sharma et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Biarylaminoquinazolines as Novel Tubulin Polymerization Inhibitors
- (2014) Giovanni Marzaro et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of 4-(N-Cycloamino)phenylquinazolines as a Novel Class of Tubulin-Polymerization Inhibitors Targeting the Colchicine Site
- (2014) Xiao-Feng Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents
- (2014) Shilong Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization
- (2014) Andrea E. Prota et al. JOURNAL OF MOLECULAR BIOLOGY
- Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
- (2013) Harish Rajak et al. CURRENT PHARMACEUTICAL DESIGN
- cis-Restricted 3-Aminopyrazole Analogues of Combretastatins: Synthesis from Plant Polyalkoxybenzenes and Biological Evaluation in the Cytotoxicity and Phenotypic Sea Urchin Embryo Assays
- (2013) Dmitry V. Tsyganov et al. JOURNAL OF NATURAL PRODUCTS
- Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly
- (2012) Sylvie Ducki Anti-Cancer Agents in Medicinal Chemistry
- Apoptosis and Human Diseases: Mitochondrion Damage and Lethal Role of Released Cytochrome c as Proapoptotic Protein
- (2012) P. Caroppi et al. CURRENT MEDICINAL CHEMISTRY
- Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones
- (2011) Niamh M. O’Boyle et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Variations in the colchicine-binding domain provide insight into the structural switch of tubulin
- (2009) A. Dorleans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)
- (2008) Jennifer J. Knox et al. INVESTIGATIONAL NEW DRUGS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now